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aim: To determine the impact of the extent of lymph node invasion (LNI) on long-term 
oncological outcomes after radical prostatectomy (RP).
Material and methods: In this retrospective study, we examined the data of 1,249 
high-risk, non-metastatic PCa patients treated with RP and pelvic lymph node dissection 
(PLND) between 1989 and 2011 at eight different tertiary institutions. We fitted univar-
iate and multivariate Cox models to assess independent predictors of cancer-specific 
survival (CSS) and overall survival (OS). The number of positive lymph node (LN) was 
dichotomized according to the most informative cutoff predicting CSS. Kaplan–Meier 
curves assessed CSS and OS rates. Only patients with at least 10 LNs removed at 
PLND were included. This cutoff was chosen as a surrogate for a well performed PNLD.
results: Mean age was 65 years (median: 66, IQR 60–70). Positive surgical margins 
were present in 53.7% (n = 671). Final Gleason score (GS) was 2–6 in 12.7% (n = 158), 
TaBle 1 | relationship between number of removed lymph nodes (lns) and number of positive lns.
no. of positive lns (%) no. of lns removed
1–4 5–9 10–14 15–19 20 or more
0 299 (90.3) 797 (80.6) 700 (74) 460 (69.4) 501 (53.8)
1–2 29 (8.8) 142 (14.4) 167 (17.7) 129 (19.5) 215 (23.1)
3 3 (0.9) 25 (2.5) 31 (3.3) 28 (4.2) 54 (5.8)
4 or more 0 25 (2.5) 48 (5.0) 46 (6.9) 161 (17.3)
Total 331 (8.6%) 989 (25.6%) 946 (24.5%) 663 (17.2%) 931 (24.1%) 3,860
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7 in 52% (n = 649), and 8–10 in 35.4% (n = 442). The median number of LNs removed 
during PLND was 15 (IQR 12–17). Of all patients, 1,128 (90.3%) had 0–3 positive LNs, 
while 126 (9.7%) had ≥4 positive LNs. Patients with 0–3 positive LNs had significantly 
better CSS outcome at 10-year follow-up compared to patients with ≥4 positive LNs 
(87 vs. 50%; p  <  0.0001). Similar results were obtained for OS, with a 72 vs. 37% 
(p < 0.0001) survival at 10 years for patients with 0–3 vs. ≥4 positive LNs, respectively. 
At multivariate analysis, final GS of 8–10, salvage ADT therapy, and ≥4 (vs. <4) positive 
LNs were predictors of worse CSS and OS. Pathological stage pT4 was an additional 
predictor of worse CSS.
conclusion: Four or more positive LNs, pathological stage pT4, and final GS of 8–10 
represent independent predictors for worse CSS in patients with high-risk PCa. Primary 
tumor biology remains a strong driver of tumor progression and patients having ≥4 
positive LNs could be considered an enriched patient group in which novel treatment 
strategies should be studied.
Keywords: high-risk prostate cancer, lymph node dissection, positive lymph node, prognosis, surgery
inTrODUcTiOn
Lymph node (LN) metastasis in men diagnosed with PCa has 
been shown to be an adverse prognostic factor for biochemical 
recurrence and survival (1, 2). To determine LN positivity, pelvic 
lymph node dissection (PLND) is the best staging method (3). 
Despite its role in staging, the therapeutic effect of PLND is still 
under debate with no study showing an effect on oncological 
outcomes (4, 5). This is possibly due to patient heterogeneity and 
the known variable presentation and evolution of high-risk PCa 
(6). Therefore, we hypothesized that the extent of lymph node 
invasion (LNI) might determine the possible therapeutic effect 
of PLND. A PLND might have a curative effect in patients with 
a low positive LN burden, whereas patients with a high positive 
LN burden might have a too high tumor extend for PLND to have 
an effect. For that reason, we determined the prognostic value of 
the extent of LNI at PLND on cancer-specific survival (CSS) and 
overall survival (OS). To achieve this, we examined a contempo-
rary series of patients with high-risk, non-metastatic PCa treated 
with radical prostatectomy (RP) and PLND at eight different 
tertiary institutions. We used the number of tumor bearing LNs 
at final pathology as a surrogate for total LN tumor burden. We 
decided to focus on high-risk PCa patients since these patients 
are at an increased risk of PSA failure, the need for secondary 
therapy, metastatic progression, and prostate cancer-related 
death (PCRD). In this series, we aimed to determine the cutoff 
number of positive LNs at which patients shift to a higher risk of 
PCRD compared to patients without affected LNs.
MaTerials anD MeThODs
Patient Population
We retrospectively analyzed the institutional RP databases of 
eight different tertiary institutions (Milan, Leuven, Munich, 
Amsterdam, Novara, Turin, Würzburg, and Krakow) and 
included all consecutive patients with a negative bone scan and 
high-risk, non-metastatic PCa defined as minimum stage cT3a 
OR minimum PSA value of 20  ng/ml OR minimum biopsy 
Gleason score (GS) of 8. All patients were primarily treated with 
RP and PLND between 1989 and 2011. As this is a retrospective 
series studying the role of PLND, there was no reliable data avail-
able on the exact anatomical extent of the PLND. It is clear that 
by removing more LNs and by extending the PLND template, 
staging accuracy increases significantly (7). Indeed, this is also 
suggested by our data when analyzing the overall patient popula-
tion, showing that with an increasing number of LNs removed, 
the number of positive LNs also increases (Table 1). Based on 
these results, we decided to only include patients in whom at least 
10 LNs were removed at PLND as a surrogate for a well performed 
TaBle 2 | Patient characteristics.
Total cohort  
(n = 1,249, 100%)
0 positive lymph node  
(ln) (n = 798, 63.9%)
1–3 positive ln  
(n = 330, 36.4%)
≥4 positive ln  
(n = 121, 9.7%)
age
Mean 65 65.1 65.1 64.3
Median (IQR) 66 (60–70) 66 (61–73) 65.4 (60–70) 66 (59.8–70)
Preoperative Psa (ng/ml)
Mean 29.8 22.1 31.2 77
Median (IQR) 18.2 (8.1–33.0) 15.2 (7.1–29) 20.8 (10.1–36.8) 35.7 (15.7–64)
Biopsy gleason score (gs), no (%)
<7 197 (19.8) 165 (20.7) 21 (6.4) 11 (9.1)
7 276 (27.7) 178 (22.3) 76 (23) 22 (18.2)
>7 524 (52.5) 306 (38.3) 156 (47.3) 62 (51.2)
Unknown 252 (20.2) 149 (18.7) 77 (23.3) 26 (21.5)
cT (UJcc 2002), no (%)
cT1–cT2 752 (62.6) 493 (61.7) 195 (59) 64 (52.9)
T3 435 (36.2) 277 (34.7) 117 (35.5) 41 (33.9)
T4 14 (1.2) 0.9 (1) 3 (1) 4 (3.3)
Unknown 48 (3.8) 21 (2.6) 15 (4.5) 4 (9.9)
neoadjuvant aDT, no (%)
No 1,092 (87.4) 708 (88.7) 280 (84.9) 104 (86)
Yes 134 (10.7) 79 (9.9) 43 (13) 12 (9.9)
Unknown 23 (1.9) 11 (1.4) 7 (2.1) 5 (4.1)
surgical margins, no (%)
Negative 578 (46.3) 375 (47%) 146 (44.2) 57 (47.1)
Positive 671 (53.7) 423 (53%) 184 (55.8) 64 (52.9)
pT (UJcc 2002), no (%)
pT2 300 (24) 282 (35.3) 14 (4.2) 4 (3.3)
pT3a 384 (30.7) 298 (37.3) 74 (22.4) 12 (9.9)
pT3b 489 (39.2) 198 (24.7) 215 (65.2) 76 (62.8)
pT4 76 (6.1) 20 (2.5) 27 (8.2) 29 (24)
Final gs, no (%)
<7 158 (12.7) 134 (16.8) 16 (4.8) 8 (6.6)
7 649 (52) 471 (59) 145 (43.9) 33 (27.3)
>7 442 (35.4) 193 (24.2) 169 (51.2) 80 (66.1)
number of ln removed, no (%)
Median 15 15 15 17
10–14 596 (47.7) 395 (49.5) 160 (48.5) 40 (33.1)
≥15 653 (52.3) 403 (50.5) 170 (51.5) 81 (66.9)
Pathological nodal status, no (%)
pN0 798 (63.9) 798 (100%) – –
pN1 451 (36.1) – 330 (100%) 121 (100%)
adjuvant therapy
RT 118 (9.44) 90 (11.3) 26 (7.9) 2 (1.7)
ADT 221 (17.7) 92 (11.5) 84 (25.5) 45 (37.2)
RT + ADT 183 (14.6) 67 (8.4) 84 (25.5) 32 (26.4)
salvage therapy
ADT 90 (8.2) 48 (6) 32 (9.7) 10 (8.3)
RT 67 (5.4) 39 (4.9) 21 (2.6) 7 (5.8)
RT + ADT 41 (3.3) 20 (2.5) 16 (2.0) 5 (4.1)
Unknown 271 (21.7) 170 (21.3) 69 (20.9) 32 (26.4)
ADT, androgen deprivation therapy; RT, radiotherapy.
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PLND. All patients included in this analysis had complete clinical 
and pathological data, including age at surgery, PSA, preopera-
tive bone scan, pathological stage defined according to the 2010 
AJCC staging system (8), specimen GS, surgical margin status, 
number of LNs removed as well as number of positive LNs, and 
type of adjuvant treatment. Data on type of salvage therapy were 
incomplete, with missing data for 271/1,249 patients. The deci-
sion to administer adjuvant or salvage therapy [i.e., androgen 
deprivation therapy (ADT) or radiation therapy (RT)] followed 
institutional protocols. ADT was generally intended to be life-
long. However, given the retrospective nature of this study, it is 
uncertain whether patients discontinued treatment after a certain 
TaBle 3 | Positive lymph nodes (lns) cutoff to predict cancer-specific 
survival and overall survival.
number of positive lns chi-squared p-Value
≥1 positive LN 11.8 0.0006
≥2 positive LNs 6.4 0.0112
≥3 positive LNs 11.5 0.0007
≥4 positive LNs 20.8 <0.0001
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period of ADT. The primary endpoint of the study was CSS and 
the secondary endpoint was OS, the latter including all men who 
had not died at last follow-up. Causes of death were determined 
by the treating physicians and confirmed by death certificates or 
autopsies if available.
statistical analysis
Kaplan–Meier analyses were performed to determine CSS and OS. 
To determine the positive LN burden most predictive for a worse 
CSS, our strategy was based on the method used by Abdollah 
et al. (9). The most informative cutoff predicting a worse CSS was 
obtained applying the chi-square test for every cutoff value of 
positive LNs up to the cutoff of ≥4 positive LNs and choosing the 
cutoff with the lowest p-value. We chose to limit the investigated 
cutoffs up to ≥4 positive LNs, since the incidence of an increasing 
number of positive LNs becomes exceedingly rare and therefore 
clinically less relevant. The number of positive LNs was then 
dichotomized according to the identified cutoff. This cutoff was 
further validated by univariate and multivariate Cox analyses to 
determine the prognostic role of positive LN burden on OS and 
CSS rates, adjusted for covariates. For all statistical analyses, a 
p-value less than 0.05 was deemed statistically significant.
resUlTs
Patient Population
Between 1989 and 2011, 4,763 patients with high-risk PCa under-
went a RP and PLND at eight different tertiary referral centers. Of 
these, the number of removed LNs and number of positive LNs 
were known in 3,860 patients (Table 1). Of the total cohort, 2,540 
patients underwent PLND with at least 10 LNs removed. After 
excluding patients with missing data, we withheld 1,249 patients 
in our final cohort. The median number of LNs removed during 
PLND was 15 (IQR 12–17), which correlates with an 80% staging 
accuracy (7). Of all patients, 47.7% (n = 596) had 10–14 nodes 
removed and 52.3% (n = 653) had 15 or more LN removed. In 
this high-risk PCa cohort, a high rate of LN metastasis (36.1% 
of patients) was confirmed. In 798 patients, nodal status was 
pN0 (63.9%); 330 patients had 1–3 positive LN (26.4%) and 126 
patients had ≥ 4 positive LN (9.7%)  (Table 2).
Baseline Patient characteristics
Baseline demographic data and clinico-pathological character-
istics of the 1,249 patients are shown in Table 2. Mean age was 
65 years (median 66, IQR 60–70) and mean PSA was 29.8 ng/
ml (median 18.2, IQR 8.1–33.0). Positive surgical margins were 
present in 53.7% (n = 671). Pathological T-stage was pT2 in 24% 
(n = 300), pT3a in 30.7% (n = 384), pT3b in 39.2% (n = 384), 
and pT4 in 6.1% (n = 76). Final GS was 2–6 in 12.7% (n = 158), 
7 in 52% (n = 649), and 8–10 in 35.4% (n = 442). Five hundred 
twenty-two patients (41.7%) received adjuvant treatment imme-
diately after surgery, of whom 221 patients (17.7%) received ADT, 
118 patients (%) received RT, and 183 (14.6%) received both ADT 
and RT. Salvage therapy was given to 198 patients (15.8%), of 
whom 90 (8.2%) received ADT, 67 (5.4%) received RT, and 41 
(3.3%) received both ADT and RT.
survival analysis
Mean follow-up for survivors was 38.5 months (median 24.3, 
IQR 11–56). Two hundred eighty-eight patients (23.1%) had 
a minimum of 5 years follow-up, and 72 patients (5.8%) had 
a minimum of 10  years follow-up. One hundred nine out 
of the 1,249 patients had died during data analysis (8.7%), 
of which 48 patients died from PCa (3.8%). We determined 
four or more positive LNs as the most informative cutoff of 
positive LNs predicting PCRD. This was obtained by applying 
the chi-square test for every cutoff value of positive LNs up 
to the cutoff of ≥4 positive LNs and choosing the cutoff with 
the lowest p-value (Table  3). Using Kaplan–Meier analysis, 
estimated 10-year CSS and OS rates are shown in Figures  1 
and 2, respectively. We then looked at CSS and OS according 
to the number of positive LNs using the cutoff of ≥4 positive 
LNs (vs. <4). The estimated 5-year CSS and OS for 0–3 positive 
nodes vs. ≥4 positive nodes were 95 vs. 73% and 89 vs. 70%, 
respectively. Estimated 10-year CSS and OS rates are shown in 
Figures 3 and 4.
cox regression analysis for css
At univariate analyses, ≥4 positive LNs [hazard ratio (HR): 
7.89, p  <  0.0001], pT3b (HR:13.4, p  =  0.01), pT4 (HR: 34.22, 
p  =  0.0006), pGS 8–10 (HR: 9.39, p  =  0.0002), positive surgi-
cal margins (HR: 3.62, p  =  0.0001), adjuvant ADT (HR: 2.1, 
p = 0.015), and salvage ADT (HR: 3.27, p = 0.004) were predic-
tors of worse CSS (Table 4). At multivariate analysis, pT4 (HR: 
2.97, p = 0.008), pGS 8–10 (HR: 3.47, p = 0.002), salvage ADT 
(HR: 2.61, p = 0.02), and the cutoff of ≥4 positive LNs (HR: 2.74, 
p =  0.03) were confirmed to be independently associated with 
worse CSS (Table 4).
cox regression analysis for Os
At univariate analyses, ≥4 positive LNs (HR: 3.29, p < 0.0001), 
pT3b (HR: 2.38, p  =  0.01), pT4 (HR: 4.69, p  <  0.0001), pGS 
8–10 (HR: 2.56, p  =  0.0004), positive surgical margins (HR: 
1.84, p = 0.002), and salvage ADT (HR: 2.45, p = 0.0015) were 
predictors of worse OS (Table 5). At multivariate analysis, pGS 
8–10 (HR: 2.39, p = 0.0003), the cutoff of ≥4 positive LNs (HR: 
2.34, p  =  0.01), and salvage ADT (HR: 2.22, p  =  0.005) were 
independently associated with worse OS (Table 5).
DiscUssiOn
Nodal metastases at the time of RP and PLND portend a poor 
prognosis. However, within the population of node-positive 
patients, a more detailed risk stratification of survival, based on 
quantification of positive LN burden, is not incorporated in the 
FigUre 1 | Kaplan–Meier estimates for cancer-specific survival according to the number of positive lymph nodes (lns) at pathologic staging. Black: 
no positive LN, blue: one positive LN, green: two positive LNs, orange: three positive LNs, and red: four or more positive LNs.
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2010 AJCC staging system of PCa. Therefore, the definition of the 
concept “positive LN burden” remains unclear since controversy 
remains regarding which characteristics of LN metastasis are 
actually significant. We focused on high-risk non-metastatic PCa 
patients, because these patients are at an increased risk of PSA 
failure, the need for secondary therapy, metastatic progression, 
FigUre 2 | Kaplan–Meier estimates for overall survival according to the number of positive lymph nodes (lns) at pathologic staging. Black: no 
positive LN, blue: one positive LN, green: two positive LNs, orange: three positive LNs, and red: four or more positive LNs.
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and death from PCa. We aimed to compare various risk factors 
including characteristics of the local tumor, number of posi-
tive LNs and therapeutic aspects in a multivariate analysis to 
FigUre 3 | Kaplan–Meier estimates for cancer-specific survival according to the cutoff of four positive lymph nodes (lns) at pathologic staging. 
Blue: less than four positive LNs and red: four or more positive LNs.
FigUre 4 | Kaplan–Meier estimates for cancer-specific survival according to the cutoff of four positive lymph nodes (lns) at pathologic staging. 
Blue: less than four positive LNs and red: four or more positive LNs.
determine the prognostic significance of each individual risk 
factor in predicting CSS and OS. Multiple important observations 
can be derived from our study.
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First, we confirmed overall excellent CSS and OS for patients 
with high-risk non-metastatic PCa treated with surgery, incor-
porated within a multimodal treatment approach. In the present 
cohort, an important role in predicting CSS appears to be rep-
resented by the number of positive LNs. Patients with 0 or 1–3 
positive LNs had non-different estimated 10-year CSS and OS of 
87 and 72%, respectively (Figure 3). Interestingly, only a quarter 
of the patients with 1–3 positive LNs received adjuvant ADT. 
About one in every 10 patients (9.7%) had 4 or more positive LNs, 
and it was only in this subset of patients that 10-year CSS and OS 
decreased significantly to 50 and 37%, respectively, even though 
approximately two-third of these patients received adjuvant ADT. 
A large retrospective analysis from the Mayo Clinic confirmed 
the finding that RP may offer long-term survival to patients 
with LN positive PCa, with 10-year CSS as high as 86% (10). In 
patients identified as LN positive at RP with extended PLND, CSS 
TaBle 5 | Uni- and multivariate analyses of predictors of a worse overall survival.
Univariate analysis Multivariate analysis
hr 95% ci p-Value hr 95% ci p-Value
PSA 1.00 0.99–1.01 NS – – NS
Age 1.02 0.99–1.05 NS – – NS
Ref. pT2 – – – – – –
pT3a 1.79 0.91–3.55 NS – – NS
pT3b 2.38 1.23–4.60 0.01 – – NS
pT4 4.69 2.27–9.72 <0.0001 – – NS
Ref. pGS 6 – – – – – –
pGS 7 0.99 0.56–1.78 NS – – –
pGS 8–10 2.56 1.51–4.31 0.0004 2.39 1.50–3.82 0.0003
Positive surgical margins 1.84 1.25–2.70 0.0020 – – NS
Ref. <4 positive LN – – – – – –
≥4 positive LN 3.41 2.05–5.65 <0.0001 2.34 1.20–4.55 0.01
Adjuvant androgen deprivation therapy (ADT) 1.07 0.73–1.57 NS – – NS
Adjuvant radiotherapy (RT) 0.67 0.41–1.08 NS – – NS
Salvage ADT 2.45 1.41–4.27 0.0015 2.22 1.27–3.88 0.005
Salvage RT 0.84 0.36–1.93 NS – – NS
HR, hazard ratio; CI, 95% confidence interval.
TaBle 4 | Uni- and multivariate analyses of predictors of a worse css.
Univariate analysis Multivariate analysis
hr 95% ci p-Value hr 95% ci p-Value
PSA 1.00 0.99–1.00 NS – – NS
Age 0.99 0.96–1.04 NS – – NS
Ref. pT2 – – – – – –
pT3a 4.91 0.61–39.26 NS – – NS
pT3b 13.4 1.81–99.10 0.01 – – NS
pT4 34.22 4.53–258.37 0.0006 2.97 1.33–6.62 0.008
Ref. pGS 6 – – – – – –
pGS7 2.13 0.59–7.77 NS – – –
pGS 8–10 9.39 2.88–30.62 0.0002 3.74 1.66–8.43 0.002
Positive surgical margins 3.62 1.88–6.9 0.0001 – – NS
Ref. <4 positive lymph node (LN) – – – – – –
≥4 positive LN 6.25 3.31–11.79 <0.0001 2.74 1.10–6.83 0.03
Adjuvant androgen deprivation therapy (ADT) 2.1 1.15–3.72 0.015 – – NS
Adjuvant radiotherapy (RT) 0.85 0.43–1.66 NS – – NS
Salvage ADT 3.27 1.46–7.35 0.004 2.61 1.15–5.95 0.02
Salvage RT 1.45 0.51–4.15 NS – – NS
HR, hazard ratio; CI, 95% confidence interval.
depended—among other variables—on the degree of LN involve-
ment. The importance of the number of tumor bearing nodes was 
emphasized again by Briganti et al. Based on their bi-institutional 
experience including 703 patients, they stated that >2 positive 
nodes represent a significant cutoff value for CSS in patients with 
node-positive PCa (11). In both above series, only pN1 patients 
were included, while patients without LN invasion but having 
the same primary tumor stage were excluded. By selecting such 
patient cohort, it is presumed a  priori that patients with posi-
tive LNs have a worse prognosis compared to pN0 patients and 
thereby rendering a potential bias. Contrary to the above studies, 
our series did not limit inclusion to pN1 patients. All high-risk 
PCa patients were equally evaluated, also including those with 
pN0 disease. This study design allowed us to determine clinical 
and pathological features predictive for CSS and OS in a real-life 
clinical situation.
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Second, our data show that patients with positive LNs are 
a highly heterogeneous group. Historically, PCa with positive 
nodes was considered as a systemic disease for which systemic 
treatment was required (12). However, our data demonstrate 
that patients with 0–3 positive nodes had an excellent survival, 
while those with ≥4 positive nodes had a far worse survival. An 
individualized and multimodal treatment approach might be 
more beneficial in this group of patients.
Third, we confirm findings by other groups showing that 
primary tumor characteristics were highly significant predictors 
for outcome in addition to positive LNs (10, 13, 14). Indeed, we 
found advanced pathological stage and pGS 8–10 to be strong 
predictors of worse CSS and OS. Importantly, pGS 8–10 showed 
to be an even stronger predictor of worse CSS compared to 
extensive nodal involvement (≥4 nodes involved). Therefore, we 
propose that patients with 0–3 positive LNs should be considered 
having loco-regional disease, with primary tumor characteristics 
remaining the predominant predictors of survival. Our findings 
provide a possible explanation for the results of recent studies by 
Da Pozzo et al., Briganti et al., and Abdollah et al. demonstrating 
improved survival with adjuvant RT in pN1 patients (15–17). 
Our observations furthermore add evidence to the concept that 
in high-risk, non-metastatic PCa, maximal control of the primary 
tumor may be of higher importance than removal of the LNs. 
Conversely, in patients with four or more positive LNs, PCa 
acquires the characteristics of systemic disease. In this subgroup, 
we hypothesize that the use of a systemic and multimodal treat-
ment might be of greater advantage than salvage radiotherapy 
alone.
Some strengths of the present study are noteworthy. First, our 
observations are based upon one of the largest series of high-
risk, non-metastatic PCa patients published to date. The results 
are reinforced by the large number of node-positive patients 
included and by the fact that these patients were treated in the 
PSA era, which renders our findings currently applicable. Second, 
a number of precedent studies used surrogate endpoints, such 
as biochemical recurrence, to evaluate the prognostic effect of 
pN1. However, we selected CSS and OS as hard study endpoints 
in order to attain relevant conclusions. Some studies, which also 
assessed hard endpoints, only analyzed an LN positive cohort, 
without taking into account pN0 patients with the same primary 
tumor stage. Such analyses are biased by presuming upfront that 
patients with one of the more positive LNs have a worse CSS 
compared to pN0 (11, 18, 19). To avoid this bias, we included 
all high-risk PCa patients in our analysis, rather than only pN1 
PCa patients and offer the possibility to determine the individual 
prognostic value of all possible individual covariate risk factors.
However, the results of our study should still be interpreted 
cautiously. First, our study is limited by biases such as the lack of 
random assignment, patient selection, incomplete data acquisi-
tion, and short time of follow-up. Second, although available for 
a subset of patients, the exact anatomical PLND template was not 
captured for the majority of patients. We compensated for this 
by only selecting patients in whom at least 10 and a median of 
15 LNs were removed, which can be considered as a reasonable 
surrogate for PLND. Nevertheless, due to the wide variation in 
number of nodes in the primary landing sites, the number of 
examined nodes might not be the best surrogate for the extent of 
the PLND and boundaries of the dissection template might be at 
least as important in defining whether all primary landing sites 
are removed (19, 20). Finally, data were generated over a long 
period of time with an unknown number of surgeons, various 
protocols for pathological assessment of the lymphadenectomy 
specimens, and varying approaches to the initiation and the con-
tinuation of adjuvant treatment. Although we aimed to evaluate 
the potential survival benefit according to the number of tumor 
bearing nodes, information of other LN-related factors such as 
nodal tumor volume, extranodal extension, lymphovascular 
invasion, and tumor differentiation were not available and hence 
were not taken into account.
Despite these limitations, this large retrospective analysis is 
hypothesis generating and should stimulate prospective studies 
stratifying disease management according to low- vs. high-
volume positive LN burden with more aggressive local treatment 
in low-volume positive LN burden and more aggressive systemic 
treatment in patients with high-volume positive LN burden.
cOnclUsiOn
Our results show favorable long-term survival outcomes for 
patients with non-metastatic high-risk prostate cancer. At mul-
tivariate analysis, 4 or more positive LNs represented an inde-
pendent predictor of worse CSS and OS, while patients with 0 vs. 
1–3 positive LNs experience similar excellent CSS. Interestingly, 
advanced pathological stage and final GS of 8–10 were additional 
important outcome predictors of worse CSS. These observations 
point to the importance of maximizing local control in high-risk 
PCa with 0–3 positive LNs. On the contrary, patients having ≥4 
positive LNs might be considered as having systemic disease and 
can be considered as an enriched patient group in which novel 
treatment strategies should be studied.
Although confirmation by prospective studies is needed, these 
results suggest that risk stratification and therapy choice should 
be individualized taking into account their LN status.
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